Purpose/Objective: Several articles have been published comparing the results of Monte Carlo (MC) simulations with treatment planning system calculations, both generally and on a site-specific basis e.g. for prostate, head and neck and lung treatments. However, publications for oesophageal radiotherapy are rare, despite the fact that the treatment volume lies in a region of heterogeneous anatomy involving a number of organs at risk (e.g. spinal cord, heart, lung). The aim of this work is to develop an efficient framework for performing MC simulations of clinical oesophageal treatments, so that the results of a statistically significant number of clinical cases may be compared in order to evaluate the differences between planning algorithms as robustly as possible. Materials and Methods: Radical oesophageal radiotherapy plans are now routinely produced in our centre according to a protocol originally developed for the UK national SCOPE trial. Plans were performed using the Pencil Beam Enhanced (PBE) and Collapsed Cone Enhanced (CCE) algorithms within Nucletron Oncentra MasterPlan (OMP v3.3 Service Pack 1). The DICOM CT, Structure Set, Plan and Dose files are exported from OMP for clinical plans. Python scripts were used to anonymise the data, remove any private DICOM tags, and alter Region Of Interest (ROIs) to follow a specific naming convention. The anonymised DICOM files were uploaded to our RTGrid calculation platform, a system that creates MC input files from DICOM files,and allows MC simulations to be performed on distributed computing resources at Cardiff University, with the results from different computers being automatically combined by the RTGrid system. The RTGrid platform has recently been adapted to handle CT scans involving iodine-based contrast agents and the Enhanced Dynamic Wedge (EDW) for Varian Linear Accelerators (linacs). After simulation, the 3D dose matrices produced by RTGrid were converted from energy deposited per photon to Gray, following the method of Liu to account for backscatter to the monitor chamber of the linac. The 3D dose matrices were then converted to DICOM-RT DOSE files, following the method of Teke. The MC dose distributions can either be imported back into OMP or, using scripts written in Matlab, in to CERR, for calculation of Dose Volume Histograms (DVHs) and other plan metrics. Results: Initial results from the study to date indicate that the dose to 95% of the Planning Target Volume (PTV) vary by up to 5%, with similar levels of difference in Organ at Risk (OAR) doses. Conclusions: A system has been developed to perform MC simulations of Oesophageal treatment plans with minimal user interaction. Initial investigations indicate that DVH parameters used in the reporting of Oesophageal treatment plans varies by up to 5% when comparing MC simulated dose distributions to those calculated from Treatment Planning algorithms.
Purpose/Objective: The majority of our breast cancer patients are treated with fixed-angle IMRT, although VMAT is also available. Fixedangle plans fulfill the clinical objectives more closely, specially in the low dose levels. In recen tyears, more precise dose calculation algorithms became available for clinical practice. Our goal is to investigate for a group of breast cancer patients whether the use of a more precise dose calculation algorithm will affect the clinical choice of IMRT plans in our institution. Materials and Methods: Five left-sided breast cancer patients were selected from a group of patients already treated with fixed-angle IMRT in our institute. Left sided tumors were chosen in order to have more insight on the dose to the heart. The clinical plans of the five patients were generated using the ECLIPSE treatment planning system (version 10). Dose calculation was performed using the AAA convolution-based algorithm. Subsequently, the clinical plans were replanned using VMAT. First, the same clinical-and optimisation objectives were used as in the plan delivered to the patient. Secondly, the VMAT plans were optimized individually in order to produce the best possible plan.
Finally, dose calculation was performed for all plans using ACUROSXB (a new deterministic-based algorithm), also available in ECLIPSE. The same calculation grid (0.25 cm) was applied. Results: Percentage differences between both VMAT and fixed-angleIMRT are larger as compared with the dose calculation algorithms (see table 1.)This is largely due to the fact that the planning objectives used for the VMATplans were originally from the fixed-angle IMRT plan. In table 1 is also shown that once an individualized optimisation is performed for the VMAT plans, differences became much less pronounced. However, results obtained for each technique show that differences of 1-3% can be found at the lower dose regions (V5 Gy), especially in the lung region. Because doses to the heart are clinically evaluated in our institute at V10 Gy instead of the V5 Gy, the differences between all the plans for this organ seem to be less significant.
Conclusions:
Differences between the dose calculation algorithms indicate that the use of ACUROSXB may affect the clinical choice of the IMRT plan. Purpose/Objective: Dose calculation algorithms might not model radiation dose distribution accurately in heterogeneous tissues (HT) such as lung and head and neck region. Latest techniques such as IMRT, IMAT and SRT produce sharp dose gradient by this means provide better dose coverage in target while reducing organs at risk (OARs) doses. Therefore accurate modeling is crucial to ensure sufficient target dose and OARs doses within tolerance limits in HT. This experimental and dosimetric study compared the dose distributions of Pencil Beam Convolution (PBC) and Anisotropic Analytical Algorithm (AAA) photon dose calculation algorithms in HT. Furthermore, IMRT plans calculated by both AAA and PBC were verified. Materials and Methods: 10 patients with non-small cell lung cancer, planned using IMRT were included. Primarily, all plans were calculated using Pencil Beam Convolution (PBC) algorithm and graded as reference plans. Than same plans were re-calculated using Anisotropic Analytical Algorithm (AAA). To ensure equal target dose coverage for both algorithms (PBC and AAA), dose normalization was made to the isodose, which is 95% of the target volume receiving 100% of the dose. OARs doses and maximum doses in the target between PBC and AAA plans were compared. Furthermore, all plans were delivered to homogeneous and heterogeneous phantoms and verification measurements made using a pinpoint ionization chamber. For each algorithm, calculated and actual doses were compared. Results: Max doses in the targets were higher for AAA than PBC plans (p=0.005); the differences were between 3.1-7.1%. Calculated OARs doses by PBC and AAA were significantly different for lung V5, V20 and Dmean (p values were 0.005, 0.005 and 0.013 respectively), for esophagus V55 and Dmean (p values were 0.005 for both criteria), and for heart V60 doses (p=0.043). Nevertheless, there was no significant difference for heart V20 (p=0.678) and spinal cord Dmax(p=0.114). Though, the differences for all OARs doses were less than 3%. Calculated and actual dose differences for homogeneous and heterogeneous phantoms were not significant for AAA plans (p=0.139 andp=0.074), although were significant for PBC plans (p=0.007 and p=0.012). Mean difference was 1.6% in AAA and 2.4% in PBC plans for homogenous phantom whereas 2.6% in AAA and 6.1% in PBC plans for heterogeneous phantom.
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